# Semaglutide Dosage: Studied Protocols and Titration Data

> Semaglutide dosage: STEP titration schedule (0.25 mg to 2.4 mg), SUSTAIN and PIONEER protocols, pharmacokinetics, and half-life data — cited from clinical trial literature.

Semaglutide is a prescription medication. All dosing decisions are made by licensed prescribers. This page documents dosing frameworks used in clinical trial protocols — not prescribing guidance.

## Dosing Frameworks Across the Trial Program

Semaglutide clinical trials used three distinct dosing frameworks: the STEP program (obesity/weight management), the SUSTAIN program (type 2 diabetes, subcutaneous), and the PIONEER program (type 2 diabetes, oral) [1, 15].

## Semaglutide Dosing Protocols in Clinical Trials

### STEP program — obesity weight management titration

| Weeks | Dose | Route |
|-------|------|-------|
| 1-4   | 0.25 mg | SC weekly |
| 5-8   | 0.5 mg  | SC weekly |
| 9-12  | 1.0 mg  | SC weekly |
| 13-16 | 1.7 mg  | SC weekly |
| 17+   | 2.4 mg  | SC weekly (maintenance) |

The slow 16-week escalation was designed to minimize gastrointestinal adverse events during initiation [1]. GI side effects were highest during dose escalation (weeks 1-20) [12].

### SUSTAIN program — type 2 diabetes (subcutaneous)

Weeks 1-4: 0.25 mg SC weekly (initiation dose). Weeks 5+: 0.5 mg maintenance; escalate to 1.0 mg if additional glycemic control needed. SUSTAIN FORTE extended to 2.0 mg: produced greater HbA1c reduction (-2.2%) versus 1.0 mg (-1.9%) and more weight loss (-6.9 kg vs -6.0 kg) in 961 patients over 40 weeks [22].

### PIONEER program — type 2 diabetes (oral)

- Initiation: 3 mg oral daily for 4 weeks
- Dose 2: 7 mg oral daily for 4 weeks or longer
- Maintenance: 14 mg oral daily
- Administration: taken 30 minutes before the first meal of the day, with water only [8, 23]

## Semaglutide Half-Life and Duration of Action

Plasma half-life: approximately 145-168 hours across studied populations, mean approximately 165 hours [8]. Subcutaneous Tmax: 24-72 hours after injection. Bioavailability: approximately 89% for subcutaneous formulation.

Time to full clearance after the final dose: approximately 5 weeks (5 × half-life ≈ 34 days) [8]. Renal or hepatic impairment does not require dose adjustment [8].

## How Long Does Semaglutide Stay in Your System?

Plasma half-life approximately 165-168 hours (approximately 7 days), enabling once-weekly dosing with stable trough concentrations at steady state [8]. Steady state is reached after 4-5 weekly doses. After the final dose, detectable drug levels persist for approximately 5 weeks. Clearance rate 0.030-0.047 L/h, volume of distribution approximately 12.5 L [8].

## Reconstitution Protocols in Published Research

Research literature on lyophilized (compounded) semaglutide preparations documents reconstitution with bacteriostatic water. Standard research concentrations: 5 mg/mL (1 mL added to a 5 mg vial) or 5 mg/mL (2 mL added to a 10 mg vial) [13].

The FDA removed semaglutide from the drug shortage list in February 2025, closing the shortage-pathway authorization for 503A pharmacy compounding after April 22, 2025, and for 503B outsourcing facilities after May 22, 2025 [13].

## References

[1] Wilding JPH et al. STEP 1. N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[6] Marso SP et al. SUSTAIN-6. N Engl J Med. 2016. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
[7] Husain M et al. PIONEER 6. N Engl J Med. 2019. https://www.nejm.org/doi/full/10.1056/NEJMoa1901118
[8] Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide. Drug Des Devel Ther. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11215664/
[12] Wilding JPH et al. STEP 1 adverse events. N Engl J Med. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[13] Foley & Lardner LLP. FDA Removes Semaglutide from Drug Shortage List. 2025. https://www.foley.com/insights/publications/2025/02/glp-1-drugs-fda-removes-semaglutide-from-drug-shortage-list/
[15] FDA Label: Semaglutide subcutaneous injection. Updated 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
[22] Rodbard HW et al. SUSTAIN FORTE. Lancet Diabetes Endocrinol. 2021. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00174-1/abstract
[23] Aroda VR et al. PIONEER 1. Diabetes Care. 2019;42(9):1724-1732. https://diabetesjournals.org/care/article/42/9/1724/36289/PIONEER-1-Randomized-Clinical-Trial-of-the

---

Clinical trial record for one compound — semaglutide — read from the primary sources and indexed here. Not a prescriber, not a vendor.